Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition

Area of Science:

• Biochemistry
• Structural Biology
• Oncology

Background:

• The L858R mutation in epidermal growth factor receptor (EGFR) is linked to non-small-cell lung cancer (NSCLC) oncogenicity, often attributed to constitutive kinase domain activation.
• Marketed EGFR inhibitors like gefitinib and erlotinib exhibit selectivity for the L858R mutant, thought to be due to specific recognition of the active kinase conformation and altered ATP binding.
• Understanding the precise structural and dynamic mechanisms underlying EGFR oncogenicity and drug response is crucial for developing more effective cancer therapies.

Purpose of the Study:

• To investigate the conformational states of L858R and L858R+T790M mutant EGFR kinase domains.
• To elucidate the interaction modes of EGFR inhibitors (gefitinib, dacomitinib) with EGFR kinase domains.
• To explore the role of conformational dynamics in the oncogenicity of EGFR mutations.

Main Methods:

• X-ray crystallography to determine the structures of EGFR kinase domains with and without inhibitors.
• Co-crystallization studies to visualize drug-binding interactions.
• Biochemical and biophysical assays to assess enzyme activity and conformational dynamics.

Main Results:

• Crystal structures revealed that neither L858R nor L858R+T790M EGFR kinase domains adopt a constitutively active conformation.
• Co-crystal structures indicated that gefitinib and dacomitinib may not be strictly conformation-specific for the active state of EGFR.
• Structural data suggested a potential recognition mechanism for the Tyr-1016 autophosphorylation site by the kinase domain.
• Biochemical and biophysical evidence pointed towards oncogenic mutations influencing the overall conformational dynamics of EGFR.

Conclusions:

• The oncogenicity of L858R EGFR may arise from altered conformational dynamics rather than constitutive activation of the kinase domain.
• EGFR inhibitors might interact with EGFR in a broader range of conformations than previously assumed.
• Understanding EGFR conformational dynamics is key to explaining mutation-driven oncogenesis and drug resistance in NSCLC.